Conference
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
Authors
Hirte HW; Vidal L; Fleming GF; Sugimoto AK; Morgan RJ; Biagi JJ; Wang L; McGill S; Ivy SP; Oza AM
Volume
26
Pagination
pp. 5521-5521
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2008
DOI
10.1200/jco.2008.26.15_suppl.5521
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X